AU2001261569A1 - Cancer treatments by using a combination of an antibody against her2 and interleukin -2 - Google Patents

Cancer treatments by using a combination of an antibody against her2 and interleukin -2

Info

Publication number
AU2001261569A1
AU2001261569A1 AU2001261569A AU6156901A AU2001261569A1 AU 2001261569 A1 AU2001261569 A1 AU 2001261569A1 AU 2001261569 A AU2001261569 A AU 2001261569A AU 6156901 A AU6156901 A AU 6156901A AU 2001261569 A1 AU2001261569 A1 AU 2001261569A1
Authority
AU
Australia
Prior art keywords
interleukin
combination
antibody against
cancer treatments
against her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261569A
Other languages
English (en)
Inventor
Michael A. Caligiuri
Neal J. Meropol
Richard L. Schilsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Arch Development Corp
Original Assignee
Health Research Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc, Arch Development Corp filed Critical Health Research Inc
Publication of AU2001261569A1 publication Critical patent/AU2001261569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2001261569A 2000-05-15 2001-05-15 Cancer treatments by using a combination of an antibody against her2 and interleukin -2 Abandoned AU2001261569A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20428400P 2000-05-15 2000-05-15
US60204284 2000-05-15
US09855342 2001-05-14
US09/855,342 US7306801B2 (en) 2000-05-15 2001-05-14 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
PCT/US2001/015525 WO2001087336A1 (fr) 2000-05-15 2001-05-15 Traitement de cancers par utilisation d'une combinaison d'un anticorps anti her2 et d'une interleukine 2

Publications (1)

Publication Number Publication Date
AU2001261569A1 true AU2001261569A1 (en) 2001-11-26

Family

ID=26899337

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261569A Abandoned AU2001261569A1 (en) 2000-05-15 2001-05-15 Cancer treatments by using a combination of an antibody against her2 and interleukin -2

Country Status (7)

Country Link
US (2) US7306801B2 (fr)
EP (1) EP1282442A1 (fr)
JP (1) JP2004501101A (fr)
AU (1) AU2001261569A1 (fr)
CA (1) CA2408974A1 (fr)
IL (1) IL152896A0 (fr)
WO (1) WO2001087336A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1282443T3 (da) * 2000-05-19 2010-01-04 Genentech Inc Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
JP4280803B2 (ja) * 2000-12-08 2009-06-17 アレクシオン ファーマシューティカルズ， インコーポレイテッド 慢性リンパ性白血病細胞株および抗体を産生するためのその使用
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2004217434B2 (en) * 2000-12-08 2010-08-26 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2003062375A2 (fr) * 2001-12-19 2003-07-31 Genentech, Inc. Stabilisation de polypeptides exposes à l'uree
US20030235556A1 (en) * 2002-01-18 2003-12-25 Chiron Corporation Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein
EP2377549A1 (fr) * 2002-06-07 2011-10-19 ZymoGenetics, Inc. Utilisation de l'IL-21 pour le traitement des infections virales
CA2492057A1 (fr) 2002-07-01 2004-01-08 Wilex Ag Coadministration de cg250 et d'il-2 ou d'ifn-alpha, destinee au traitement de cancers tels que les hypernephromes
EP2425847A1 (fr) * 2004-05-20 2012-03-07 ZymoGenetics, Inc. Procédés pour traiter le cancer au moyen d'IL-21 et une thérapie par anticorps monoclonaux
CN102580084B (zh) * 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
WO2006084058A2 (fr) 2005-02-03 2006-08-10 The General Hospital Corporation Methode de traitement du cancer resistant au gefitinib
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
WO2006096861A2 (fr) * 2005-03-08 2006-09-14 Genentech, Inc. Methodes permettant d'identifier des tumeurs sensibles au traitement par des inhibiteurs de dimerisation her (hdi)
WO2006098978A1 (fr) * 2005-03-09 2006-09-21 Abbott Laboratories Procede diagnostique d’identification des patients candidats a un traitement au trastuzumab
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
WO2007056118A1 (fr) * 2005-11-04 2007-05-18 Wyeth Combinaisons antineoplasiques a base d'inhibiteur de mtop, d'herceptine et/ou de khi-272
US20070111906A1 (en) * 2005-11-12 2007-05-17 Milner Jeffrey L Relatively low viscosity transmission fluids
DK2463305T3 (en) 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
PL2511301T3 (pl) 2006-08-04 2018-05-30 Medimmune Limited Ludzkie przeciwciała do ErbB2
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
ES2583377T3 (es) * 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
KR20100036362A (ko) * 2007-07-25 2010-04-07 알렉시온 파마슈티칼스, 인코포레이티드 자가면역 질환 치료 방법 및 조성물
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2915532B1 (fr) 2008-06-17 2016-10-19 Wyeth LLC Combinaisons antinéoplasiques contenant du HKI-272 et de la vinorelbine
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
WO2010051502A2 (fr) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Molécules ciblant light et leurs utilisations
SG174378A1 (en) 2009-03-20 2011-10-28 Genentech Inc Bispecific anti-her antibodies
EP3000467B1 (fr) 2009-04-06 2023-03-01 Wyeth LLC Régime de traitement à l'aide de nératinib pour le cancer du sein
CA2761280A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
WO2011100538A1 (fr) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Procédés thérapeutiques utilisant des anticorps anti-cd200
EP2536748B1 (fr) 2010-02-18 2014-08-20 Genentech, Inc. Antagonistes de la neuréguline et leur utilisation dans le cadre du traitement du cancer
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
EP2655413B1 (fr) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
CA2842375A1 (fr) 2011-08-17 2013-02-21 Erica Jackson Anticorps anti-neureguline et utilisations associees
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2014126098A (ru) 2011-11-30 2016-01-27 Дженентек, Инк. МУТАЦИИ ErbB3 ПРИ РАКЕ
WO2013083810A1 (fr) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification de non-répondeurs aux inhibiteurs de her2
WO2013148315A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
KR101453462B1 (ko) * 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
HUE054529T2 (hu) 2014-03-11 2021-09-28 Molecular Templates Inc Amino-terminális proximális Shiga toxin A alegység effektor régiókat és sejtcélzó immunglobulin-típusú kötõrégiókat tartalmazó proteinek, amelyek képesek CD38 specifikus kötésére
BR112016022910A2 (pt) 2014-04-11 2017-10-17 Medimmune Llc anticorpos contra her2 biespecíficos
US9586056B2 (en) 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
WO2016052971A1 (fr) * 2014-09-30 2016-04-07 가톨릭대학교 산학협력단 Conjugué herceptine-photosensibilisant destiné au diagnostic du cancer et son procédé de production
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
EP3325510A2 (fr) 2015-07-26 2018-05-30 Molecular Templates, Inc. Molécules de ciblage de cellules comprenant des effecteurs de sous-unité de shiga-toxines a et des épitopes de lymphocytes t cd8+
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
EP3596108A4 (fr) 2017-03-15 2020-12-23 Pandion Operations, Inc. Immunotolérance ciblée
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2019067499A1 (fr) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
WO2019204272A1 (fr) 2018-04-17 2019-10-24 Molecular Templates, Inc. Molécules ciblant her2 comprenant des matrices de la sous-unité a, rendue non immunogène, de la shigatoxine
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360942A (ja) * 1986-08-01 1988-03-17 シタス　コ−ポレイシヨン インタ−ロイキン−２と共に免疫毒素又は抗体を用いてのコンビネ−ション治療
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US20030235556A1 (en) * 2002-01-18 2003-12-25 Chiron Corporation Combination IL-2/anti-HER2 antibody therapy for cancers characterized by overexpression of the HER2 receptor protein

Also Published As

Publication number Publication date
US20020031515A1 (en) 2002-03-14
EP1282442A1 (fr) 2003-02-12
IL152896A0 (en) 2003-06-24
US7306801B2 (en) 2007-12-11
US20080159981A1 (en) 2008-07-03
CA2408974A1 (fr) 2001-11-22
JP2004501101A (ja) 2004-01-15
WO2001087336A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2001261569A1 (en) Cancer treatments by using a combination of an antibody against her2 and interleukin -2
AUPR395801A0 (en) Antibodies against cancer
AU2002348477A1 (en) Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
AU2002247304A1 (en) Anti-neovasculature preparations for cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002220843A1 (en) Humanised antibodies and uses thereof
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002359720A1 (en) Supplemental interlabial device
AU2001290860A1 (en) Spas-1 cancer antigen
AU2001260876A1 (en) Radiation therapy device with miniaturized radiation source
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU2002329989A1 (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2002351374A1 (en) Antibodies to treat cancer
AU2003219696A1 (en) Sga-1m, a cancer associated antigen, and uses thereof
AU2002227272A1 (en) Ovarian tumor antigen and methods of use therefor
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001257325A1 (en) Cancer treatment
AU7832700A (en) Ovarian tumor antigen and methods of use therefor
AU5632500A (en) Cancer associated antigens and uses therefor
AU2001247286A1 (en) Integrated optical transceiver and related methods
AU2002305138A1 (en) Methods and materials for cancer treatment
AUPR589001A0 (en) An antibody cancer therapeutic
AU2001274946A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer